Navigation Links
ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing
Date:8/23/2009

LEIDEN, The Netherlands and SEATTLE, August 24 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.

Jaap Koopman, PhD, Chief Executive Officer, said: "We are very pleased to welcome Gilde Healthcare to our investor base and we appreciate the ongoing support and expertise that our investors can offer to our experienced team as we continue the development of ProFibrix. The proceeds of the financing will be applied to the ongoing clinical development of our lead product Fibrocaps(TM), and to the preclinical development of our pipeline products."

Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical tissue sealant that rapidly stops bleeding after or during surgery. Fibrocaps has major advantages over existing liquid tissue sealants: it is ready for immediate use, is stable at room temperature, highly effective and fast acting. Fibrocaps is currently in a Phase II clinical trial in the Netherlands with results expected end of 2009.

Dirk Kersten, investment manager at Gilde Healthcare Partners, commented: "Gilde Healthcare Partners invests in biopharmaceutical companies with strong technology platforms and experienced management. We believe ProFibrix' breakthrough fibrinogen technology is well-positioned to play an important role in the highly attractive hemostasis and regenerative medicine markets."

ProFibrix expects to submit an Investigational New Drug Application (IND) for Fibrocaps to the U.S. Food and Drug Administration in the f
'/>"/>

SOURCE ProFibrix B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Enobia Raises US$50M from Current Investors in Series C Financing
2. TSH Testing Raises Awareness of Importance of Thyroid Health
3. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
4. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
5. Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
6. Americans United for Life: Obamas Disbanding Bioethics Council Raises Troubling Questions
7. Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million
8. Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance
9. Marinus Pharmaceuticals Raises $20 Million in Series B Financing
10. BioVex Raises $40 Million in First Close of Series F Financing
11. Moodys Raises Boston Scientifics Rating Outlook to Stable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... RESEARCH TRIANGLE PARK, N.C. , Aug. 27, ... reports on the decision by FedEx, UPS and ... shipments of certain biological specimens classified as ,select ... expertise and long history of handling these sensitive ... network, knowledge of global transportation regulations, trained and ...
(Date:8/26/2015)... Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... advanced testing solutions for the detection of foodborne pathogens, ... at the Sidoti & Company Emerging Growth Conference on ... held at the New York Marriott Marquis. ... available through the investor relations section of Roka Bioscience,s ...
(Date:8/26/2015)... Aug. 26, 2015 Intrexon Corporation (NYSE: ... the closing of its previously announced public offering of ... underwriters of their option to purchase an additional 731,707 ... of $41.00 per share.  The exercise of the underwriters, ... stock sold by Intrexon to 5,609,756 shares and increased ...
(Date:8/26/2015)... , August 26, 2015 ... biggest factors fueling the optimism in biotech,s forecast ... collaborations and life sciences advancements.  Active biotechnology & ... Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: ... SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: RPTP ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... , ATLANTA, Sept. 21 GeoVax ... Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by ... that it has requested a pre-Investigational New Drug (IND) meeting ... a proposed IND for GeoVax,s therapeutic vaccine as a treatment ...
... , RANCHO CORDOVA, Calif., Sept. 21 ThermoGenesis Corp. ... for processing and storing adult stem cells, said today it had ... become non-compliant with the Nasdaq Capital Markets, minimum bid pricing requirement ... past 30 days had failed to meet the minimum bid of ...
... , CAMBRIDGE, Mass., Sept. 21 Merrimack ... the company as Senior Vice President, Development. Dr. Niyikiza comes ... and Medicine Development Leader for oncology. Dr. Niyikiza has ... over 18 years in the pharmaceutical industry in which he ...
Cached Biology Technology:GeoVax Labs Requests pre-IND Meeting With FDA 2GeoVax Labs Requests pre-IND Meeting With FDA 3ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule 2ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule 3Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2
(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... 12-hour, dual-stage surgery known to be performed at only ... University of Alabama at Birmingham on Tuesday returned a ... his pancreas to eliminate constant, severe pain from chronic ... City, Fla., remained anesthetized in the operating room at ...
... new way to sabotage DNA's ability to reproduce, a ... new anti-cancer drugs and therapies. , The method could ... than directing chemotherapeutic medication or radiation to tumors through ... in the university's Zanvyl Krieger School of Arts and ...
... that does not require oxygen, Penn State environmental engineers ... the first process that enables bacteria to coax four ... can be generated typically by fermentation alone. , Dr. ... an inventor of the MFC, says, "This MFC process ...
Cached Biology News:Rare surgery performed to remove pancreas, prevent diabetes 2Microbial fuel cell: High yield hydrogen source and wastewater cleaner 2
... For real-time or pre-programmed ... biophysics, electrochemistry, or general liquid-handling ... 10 millisecond accuracy. ... unattended Microprocessor-based for accuracy ...
... 10. *SizeSep 400 Spun Columns: For rapid ... in length. - ... distilled water containing 0.15% Kathon CG/IcP Biocide. ... pairs. *Extremely useful in the construction ...
... The Light Diagnostics Universal Amplicon ... for use in the qualitative ... generated by in vitro ... use only; not to be ...
... 25 purifications. Allows rapid purification ... removal of unincorporated CyDye label and ... yields of labeled cDNA probe. ... labeled by either direct incorporation or ...
Biology Products: